60 Degrees Pharmaceuticals (SXTP) EBIT (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly EBIT of -$2.1 million for Q1 2026, down 9.63% year-over-year from -$2.3 million in Q1 2025, and down 9.26% quarter-over-quarter from -$1.9 million in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) EBIT (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported EBIT for 5 consecutive years, with -$2.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT fell 9.63% year-over-year to -$2.1 million; the TTM figure through Mar 2026 stood at -$7.9 million (up 22.76% YoY), while the FY2025 annual figure was -$7.8 million, up 20.14% from the prior year.
- EBIT declined to -$2.1 million in Q1 2026 per SXTP's latest filing, from -$1.9 million in the prior quarter.
- Across five years, EBIT topped out at -$215116.0 in Q3 2022 and bottomed at -$4.2 million in Q2 2024.
- Historically, EBIT has averaged -$1.6 million across 5 years, with a median of -$1.7 million in 2023.
- Annual changes were most pronounced in 2023 — EBIT slumped 607.41% — and 2025, when it jumped 61.69%.
- 60 Degrees Pharmaceuticals' EBIT stood at -$684698.0 in 2022, then tumbled by 176.64% to -$1.9 million in 2023, then dropped by 9.03% to -$2.1 million in 2024, then advanced by 7.16% to -$1.9 million in 2025, then decreased by 9.26% to -$2.1 million in 2026.
- Business Quant data shows SXTP's EBIT at -$2.1 million in Q1 2026, -$1.9 million in Q4 2025, and -$2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | 60 Degrees Pharmaceuticals | 2.97 Mn | 1.95 Mn | 56,798.00 | -2.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.09 Mn |
| Dec 31, 2025 | -1.92 Mn |
| Sep 30, 2025 | -2.33 Mn |
| Jun 30, 2025 | -1.60 Mn |
| Mar 31, 2025 | -1.91 Mn |
| Dec 31, 2024 | -2.07 Mn |
| Sep 30, 2024 | -2.12 Mn |
| Jun 30, 2024 | -4.19 Mn |
| Mar 31, 2024 | -1.34 Mn |
| Dec 31, 2023 | -1.89 Mn |
| Sep 30, 2023 | -1.52 Mn |
| Jun 30, 2023 | -787,996.00 |
| Mar 31, 2023 | -950,664.00 |
| Dec 31, 2022 | -684,698.00 |
| Sep 30, 2022 | -215,116.00 |
| Jun 30, 2022 | -686,919.00 |